The global acute coronary syndrome therapeutic market demand is expected to witness considerable growth over the forecast period. ACS or Acute Coronary Syndrome refers to the set of conditions which occurs on account of decreasing flow of blood in coronary arteries owing to which the heart muscle is not able to function. There are various symptoms associated with this condition. The most commonly occurring symptom includes chest pain, sweating, and nausea. With changing lifestyle, eating habits and sleepless nights some disorders are associated with it such as diabetes, rising cholesterol level, and obesity. Also, various other factors such as hypertension, growing adoption of drug and smoking habits are also leading to the growth. If all these disorders are not properly treated at an early stage, then it may lead to early heart attacks. Healthcare infrastructure is improving to support various medical treatments related to such disorders, which will eventually result in the growth of the acute coronary syndrome market. Developed countries are more affected by these disorders as compared to other developing nations.
Acute coronary syndrome market is segmented into various branded drugs and thousands of generic medicines. Generic drugs generate more revenue as compared to the branded drugs. There are three types of major syndromes: ST elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina. Very frequent occurrence of Unstable angina, followed by ST elevation myocardial infarction and non-ST elevation myocardial infarction are expected to dominate the market. Unstable angina occurs when the body suffers a shortage of blood flow and oxygen, which may eventually lead to heart attack. NonST elevation myocardial infarction occurs when the coronary arteries are partially blocked by blood clots and ST elevation myocardial elevation occurs when the coronary arteries are entirely blocked by the blood clots which may result in the death of the patient. There are several global companies who are present in the acute coronary syndrome therapeutic market and are evaluating new branded drugs to help patients to recover. There are situations where several new drugs have resulted in the death of patients, and therefore, sales of these drugs have declined rapidly. Hence overcoming this challenge will be an important factor over the next seven years. Governments are supporting research for developing new drugs to expand the industry. Increasing disposable income in emerging economies is expected to play a significant role in boosting sales of these branded drugs. It is anticipated to provide new opportunities for new companies entering the pharmaceutical industry.
The generic drugs and branded drugs related to the acute coronary syndrome apply to the cardiology department of any medical treatment facilities. The current treatments focus on the novel pathways for the treatment of ACS. Various branded drugs are expected to enter the acute coronary syndrome therapeutic market over the next few years. Top promising drugs include Losmapimod, Praluent, Repatha, and Xarelto. The share of branded drugs is supposed to be more than 60 percent of the total ACS industry.
Asia-Pacific, Europe, and MEA are expected to be key regions for this industry over the forecast period. In, 2014 North America and Europe were the dominant areas. Rising awareness about this disease in the U.S. has made it the largest acute coronary syndrome therapeutic market and followed by Canada. With, rising disposable income in emerging economies such as India and China are expected to play a significant role in the expansion of this industry over the forecast period.
Some of the key players in the ACS sector include Arena Pharmaceuticals, Artery Therapeutics, Athera Biotechnologies, Bayer AG, Cardiome Pharma Corp., Cerenis Therapeutics Holding SA, Esperion Therapeutics, GlaxoSmithLline Plc, Lee’s Pharma Corp., Pfizer Inc., Teva Pharmaceutical Industries Ltd. The Medicines Co, Vitae Pharmaceuticals, Inc. and XOMA Corporation. There are a number of strategies which are being used by the pharma companies for the Acute Coronary Syndrome market. Amgen’s Repatha has used a clinical trial program named PROFICIO for testing the patient's LDL-C and cardiovascular outcomes. There have been ten clinical phase trials. Merck is developing MK-0859 to treat hypercholesterolemia and prevent cardiovascular disease. There is a large number of players present in the acute coronary syndrome market and to survive companies need to adopt different strategies which include new product development, mergers, and acquisitions with the global players.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.